Showing posts with label patient. Show all posts
Showing posts with label patient. Show all posts

Sunday, January 29, 2012

HHS launches health IT challenge to improve care transitions for hospital-discharge patients


January 26, 2012. The National Coordinator for Health Information Technology today announced a Discharge Follow-Up Appointment care transitions challenge – the second as part of the Office of the National Coordinator for Health Information Technology (ONC) Investing in Innovation (i2) Initiative.  With the support of Health 2.0 and Partnership for Patients, ONC launched the Discharge Follow-Up Appointment challenge in support of ONC’s Investing in Innovation (i2) program.

The i2 Initiative is a bold new effort to spur innovations in health IT.  The program utilizes prizes and challenges to facilitate innovation and obtain solutions to intractable health IT problems.  Aligned with the Obama administration’s innovation agenda, i2 is the first federal program to operate under the authority of the America COMPETES Reauthorization Act of 2010.
Today’s challenge aims to stimulate the use of simple, information technology-enabled processes and tools to make transitions easier and safer for patients, caregivers and providers, particularly when a patient is discharged from a hospital.  The first health IT challenge, Ensuring Safe Transitions from Hospital to Home Exit disclaimer, called upon developers to create a web-based application that could empower patients and caregivers to better navigate and manage a transition from a hospital.
This latest challenge was announced during today’s Care Innovations Summit. The Summit is co-hosted by the ONC, the Centers for Medicare & Medicaid Services, the West Wireless Health Institute and Health Affairs to call attention to importance of care transitions and address the gaps in care coordination with a focus on better care and better health at a lower cost.
The scheduling of follow-up appointments and post-discharge testing before leaving the hospital helps ensure safer and more effective transitions.  Unfortunately, most patients across the country continue to leave the hospital without confirmed appointments and many providers remain frustrated by a highly manual and unreliable system.  The Discharge Follow-Up Appointment challenge will focus on promoting effective care transitions.
“This challenge is an enormous opportunity for software developers to develop solutions, and pursue models that can be adopted across a community,” said Farzad Mostashari, M.D., Sc.M., national coordinator for health information technology.  “Scheduling post-discharge follow-up appointments is critical, but not easy for patients or providers and we’re excited by the possibilities that will stem from this challenge.”
For additional information about ONC or on the i2 program, visit http://HealthIT.HHS.gov.
For more information about Health 2.0, which helps support the i2 challenge program, visit www.Health2Con.com Exit disclaimer.
For more information about Partnership for Patients, which also supports the i2 challenge program, visithttp://www.healthcare.gov/compare/partnership-for-patients/index.html .
For more information about U. S. Department of Health and Human Services’ Recovery Act programs, seewww.hhs.gov/recovery.


x

Thursday, December 15, 2011

Partnership for Patients initiative to improve hospital care

FOR IMMEDIATE RELEASE.December 14, 2011. Hospitals across the country will have new resources and support to make health care safer and less costly by targeting and reducing the millions of preventable injuries and complications from healthcare acquired conditions, the U.S. Department of Health and Human Services (HHS) announced.  As a part of the Partnership for Patients initiative, a nationwide public-private collaboration to improve the quality, safety, and affordability of health care for all Americans, $218 million will go to 26 state, regional, national, or hospital system organizations. As Hospital Engagement Networks, these organizations will help identify solutions already working to reduce healthcare acquired conditions, and work to spread them to other hospitals and health care providers.

“At some point in our lives many of us are going to need hospital care and we need to be confident that no matter where we live, we’re going to get the best care in the world,” said HHS Secretary Kathleen Sebelius.  “The Partnership for Patients is helping the nation’s finest health systems share their knowledge and resources to make sure every hospital knows how to provide all of its patients with the highest quality care.”

The Hospital Engagement Networks’ will be funded with $500 million from the Centers for Medicare & Medicaid Services Innovation Center, which was established by the Affordable Care Act.  Hospital Engagement Networks will work to develop learning collaboratives for hospitals and provide a wide array of initiatives and activities to improve patient safety.  They will be required to conduct intensive training programs to teach and support hospitals in making patient care safer, provide technical assistance to hospitals so that hospitals can achieve quality measurement goals, and establish and implement a system to track and monitor hospital progress in meeting quality improvement goals.  The activities of the Hospital Engagement Networks will be closely monitored by CMS to ensure that they are improving patient safety.

Launched in April 2011, the Partnership for Patients now consists of more than 6,500 partners, including over 3,167 hospitals, along with 2345 physicians, nurses, patient advocates, 892 consumers and consumer groups, and 256 employers and unions. In addition, health plans, Area Agencies on Aging, and state and federal government officials who have pledged to work together to reduce the number of hospital-acquired conditions by 40 percent and reduce hospital readmissions by 20 percent by the end of 2013.

“In just the past eight months we’ve seen an overwhelming response from doctors, employers, patient advocates and other partners who believe the time is now to improve patient safety—as a former ICU nurse and hospital administrator, I’m proud to see hospitals stepping up to the plate,” said Marilyn Tavenner, acting administrator of CMS, the HHS agency sponsoring the program.  “We look forward to working with the Hospital Engagement Networks and the hospitals on the critical and important work of making care safer, more reliable, and less costly and achieving the goals of the Partnership for Patients.”
Achieving the Partnership for Patients’ objectives would mean approximately 1.8 million fewer injuries to patients in the hospital, saving over 60,000 lives over three years, and would mean more than 1.6 million patients to recover from illness without suffering a preventable complication requiring re-hospitalization.

The 26 organizations receiving awards are:

American Hospital Association;
Ascension Health;
Carolinas HealthCare System;
Catholic Healthcare West;
Dallas-Fort Worth Hospital Council Foundation;
Georgia Hospital Association Research and Education Foundation;
Healthcare Association of New York State;
Hospital & Healthsystem Association of Pennsylvania;
Intermountain Healthcare;
Iowa Healthcare Collaborative;
Joint Commission Resources, Inc.;
Lifepoint Hospitals, Inc.;
Michigan Health & Hospital Association;
Minnesota Hospital Association;
National Public Health and Hospital Institute;
New Jersey Hospital Association;
Nevada Hospital Association;
North Carolina Hospital Association;
Ohio Children’s Hospital Solutions for Patient Safety;
Ohio Hospital Association;
Premier;
Tennessee Hospital Association;
Texas Center for Quality & Patient Safety;
UHC;
VHA; and
Washington State Hospital Association.

HHS has committed up to $1 billion in Affordable Care Act funding to help achieve the Partnership for Patients.  In addition to the funding to help reduce health care acquired conditions, $500 million has been made available through the Community-Based Care Transitions Program to ensure patients safely transition between settings of care to bring down readmissions.  Recently, seven organizations were selected as the first participants for the Community-Based Care Transitions Program.

In addition to the Hospital Engagement Contract awards, HHS has awarded three other contracts to assist in achieving the Partnership for Patients’ goals: the National Content Developer Contractor, the Beneficiary and Medical Professional Engagement Contractor, and the Evaluation Contractor.

For more information on the Partnership for Patients, please visit http://www.healthcare.gov/partnershipforpatients.

x

Monday, November 28, 2011

Standardizing Medication Labels:Confusing Patients Less

Medications are an important component of health care, but each year their misuse results in over a million adverse drug events that lead to office and emergency room visits as well as hospitalizations and, in some cases, death. As a patient's most tangible source of information about what drug has been prescribed and how that drug is to be taken, the label on a container of prescription medication is a crucial line of defense against such medication safety problems, yet almost half of all patients misunderstand label instructions about how to take their medicines.

Standardizing Medication Labels: Confusing Patients Less is the summary of a workshop, held in Washington, D.C. on October 12, 2007, that was organized to examine what is known about how medication container labeling affects patient safety and to discuss approaches to addressing identified problems.

Workshop Summary.Topics:Quality and Patient Safety,Select Populations and Health Disparities.Activity: Roundtable on Health Literacy.Board: Board on Population Health and Public Health Practice

Standardizing Medication Labels: Confusing Patients Less - Workshop Summary
a

Monday, November 21, 2011

FDA approves Eylea for eye disorder in older people

FDA NEWS RELEASE.For Immediate Release: Nov. 18,2011. Maintains clearness of vision in those with wet age-related macular degeneration.The U.S. Food and Drug Administration today approved Eylea (aflibercept) to treat patients with wet (neovascular) age-related macular degeneration (AMD), a leading cause of vision loss and blindness in Americans ages 60 and older.
AMD gradually destroys a person’s sharp, central vision. It affects the macula, the part of the eye that allows people to see fine detail needed to do daily tasks such as reading and driving.
There are two forms of AMD, a wet form and a dry form. The wet form of AMD includes the growth of abnormal blood vessels. The blood vessels can leak fluid into the central part of the retina, also known as the macula. When fluid leaks into the macula, the macula thickens and vision loss occurs. An early symptom of wet AMD occurs when straight lines appear to be wavy.
“Eylea is an important new treatment option for adults with wet AMD,” said Edward Cox, M.D., M.P.H, director of the Office of Antimicrobial Products in FDA’s Center for Drug Evaluation and Research. “It is a potentially blinding disease and the availability of new treatment options is important.”
The safety and effectiveness of Eylea was evaluated in two clinical trials involving 2,412 adult patients. People in the study received either Eylea or Lucentis (ranibizumab injection). The primary endpoint in each study was a patient’s clearness of vision (visual acuity) after one year of treatment.
Eylea is injected into the eye either every four weeks or every eight weeks by an ophthalmologist. The studies showed that Eylea was as effective as Lucentis in maintaining or improving visual acuity.
The most commonly reported side effects in patients receiving Eylea included eye pain, blood at the injection site (conjunctival hemorrhage), the appearance of floating spots in a person’s vision (vitreous floaters), clouding of the eye lens (cataract), and an increase in eye pressure.
Eylea should not be used in those who have an active eye infection or active ocular inflammation. Eylea has not been studied in pregnant women, so the treatment should be used only in pregnant women if the potential benefits of the treatment outweigh any potential risks. Age related macular degeneration does not occur in children and Eylea has not been studied in children.
Other FDA-approved treatment options for wet AMD include: Visudyne (verteporfin for injection) approved in 2000, Macugen (pegaptanib sodium injection) approved in 2004, and Lucentis (ranibizumab injection) approved in 2006.
Eylea is marketed by Tarrytown, N.Y.-based Regeneron Pharmaceuticals Inc.
For more information:
NEI: Facts about Age-Related Macular Degeneration

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.
Media Inquiries: Erica Jefferson, 301-796-4988, erica.jefferson@fda.hhs.gov. Consumer Inquiries: 888-INFO-FDA

Wednesday, November 16, 2011

FDA approves first drug to treat a rare bone marrow disease

FDA NEWS RELEASE. For Immediate Release: Nov. 16, 2011. The U.S. Food and Drug Administration today approved Jakafi (ruxolitinib), the first drug approved to specifically treat patients with the bone marrow disease myelofibrosis. Myelofibrosis is a disease in which the bone marrow is replaced by scar tissue resulting in blood cells being made in organs such as the liver and the spleen. This disease is marked by an enlarged spleen, anemia, decreased white blood cells and platelets, and myelofibrosis-related symptoms.

Symptoms include fatigue, abdominal discomfort, pain under the ribs, feeling full (satiety), muscle and bone pain, itching, and night sweats. Jakafi, a pill taken two times a day, inhibits enzymes called JAK 1 and 2 (JanuAssociated Kinase) that are involved in regulating blood and immunological functioning. Myelofibrosis is associated with the deregulation of JAK 1 and 2.

“Jakafi represents another example of an increasing trend in oncology where a detailed scientific understanding of the mechanisms of a disease allows a drug to be directed toward specific molecular pathways,” said Richard Pazdur, M.D., director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research. “The clinical trials leading to this approval focused on problems that patients with myelofibrosis commonly encounter, including enlarged spleens and pain.”

The safety and effectiveness of Jakafi was evaluated in two clinical trials with 528 patients. Patients in both trials were resistant or refractory to available myelofibrosis therapy or ineligible for allogeneic bone marrow transplantation (procedure where a person receives blood-forming stem cells from a genetically similar, but not necessarily identical, donor). All patients had enlarged spleens (splenomegaly) and were in need of treatment as a result of disease-related symptoms.

Patients in the studies were selected to receive treatment with either Jakafi, placebo (sugar pill) or the best available therapy (hydroxyurea, a chemotherapy agent, or glucocorticoids). A greater percentage of patients receiving Jakafi experienced more than a 35 percent reduction in spleen size when compared to patients receiving placebo or best available therapy. Similarly, a greater proportion of patients receiving Jakafi saw more than a 50 percent reduction in their myelofibrosis-related symptoms, including abdominal discomfort, night sweats, itching and bone or muscle pain, than was the case in patients receiving placebo.

The most serious side effects seen in patients treated with Jakafi include low blood platelet levels (thrombocytopenia), anemia, fatigue, diarrhea, shortness of breath (dyspnea), headache, dizziness, and nausea.

Jakafi was reviewed under the FDA’s priority review program, an expedited six-month review of drugs that may offer significant advances in treatment over available therapy or that provide a treatment when no adequate therapy exists.

The treatment is being approved ahead of the drug’s Dec. 3, 2011 review goal date under the Prescription Drug User Fee Act and has been designated as an orphan drug, which identifies the disease as affecting fewer than 200,000 people in the U.S.

Jakafi is manufactured by Incyte Corp. of Wilmington, Del.
For more information:

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.
For Immediate Release: Nov. 16, 2011. Media Inquiries: Erica Jefferson, 301-796-4988, erica.jefferson@fda.hhs.gov Consumer Inquiries: 888-INFO-FDA

Tuesday, November 8, 2011

Health IT and Patient Safety: Building Safer Systems for Better Care

In their continuous efforts to improve health care, both the public and private sectors have invested—and continue to invest—heavily in health information technologies, collectively referred to as health IT. When designed and used appropriately, health IT is expected to help improve the performance of health professionals, reduce operational and administrative costs, and enhance patient safety.
However, some products have begun being associated with increased safety risks for patients. The Office of the National Coordinator for Health Information Technology (ONC), the unit within the Department of Health and Human Services (HHS) that is responsible for coordinating the development of a national health IT infrastructure and promoting the use of health IT, asked the Institute of Medicine (IOM) to evaluate safety concerns and to identify actions that both government and the private sector can take to alleviate those actions. The IOM appointed a study committee, which interpreted its charge as recommending ways to make patient care safer using health IT so that the nation will be in a better position to realize its potential benefits.
Critical Knowledge Gaps and Barriers
In its report, Health IT and Patient Safety: Building Safer Systems for Better Care, the committee examines the safety of health IT products and their effects on patient safety. Overall, the committee finds the literature about health IT and patient safety to be inconclusive. Some health IT applications are definitively successful at improving medication safety. For example, the number of patients who receive the correct medication in hospitals increases when these hospitals implement well-planned, robust computerized prescribing mechanisms and use barcoding systems. But even in these instances, the ability to generalize the results across the health care system may be limited. For other products— including electronic health records, which are being employed with more and more frequency— some studies find improvements in patient safety, while other studies find no effect.
More worrisome, some case reports suggest that poorly designed health IT can create new hazards in the already complex delivery of care. Although the magnitude of the risk associated with health IT is not known, some examples illustrate the concerns. Dosing errors, failure to detect life-threatening illnesses, and delaying treatment due to poor human–computer interactions or loss of data have led to serious injury and death.
Fostering a Systems Approach
In looking for ways to make health IT–assisted care safer, it is important to recognize that the products are not used in isolation. Rather, they are part of a larger sociotechnical system that also includes people—such as clinicians or patients— organizations, processes, and the external environment. Safety emerges from the interactions of these factors. Comprehensive safety analyses, therefore, should not look for a single “root cause” of problems but should consider the system as a whole in looking for ways to reduce the likelihood that any given patient will experience an adverse health event.
Creating safer systems begins with usercentered design principles and includes adequate testing and quality assurance assessments conducted in actual or simulated clinical environments, or both. Designers and users of health IT should work together to develop, implement, optimize, and maintain health IT products. For most end users, an effective health IT product will provide easy retrieval of accurate, timely, and reliable data; incorporate simple and intuitive data displays; and yield evidence at the point of care to inform decisions. Among other improvements, the product will
  • enhance workflow, perhaps by automating mundane tasks or streamlining work, without increasing physical or cognitive workloads;
  • allow easy transfer of information to and from other organizations and providers; and
  • cause no unanticipated downtime.

Promoting Sharing of Safety Data
While the private sector, including health IT vendors, users, patients, and professional societies, must play a major role in improving safety, the government can help in various ways. As one step, HHS should ensure that vendors support users in freely exchanging information about health IT experiences and issues, including details relating to patient safety. The ability to generate, develop, and share details of safety risks is essential to a properly functioning market in which health care providers have the ability to choose products that best suit their needs. Currently, many contracts with vendors include clauses that could impede efforts to improve patient safety. For example, nondisclosure clauses can discourage users from sharing information, and limited liability clauses can essentially shift liability from the vendor to the users when an adverse event occurs.
The ONC also should work with the private sector to make comparative user experiences publicly available. In other industries, public product reviews allow users to rate their experiences with products and share lessons learned. A consumer guide for health IT safety could help identify safety concerns, increasing system transparency.
Improving Standards, Measures, and Criteria for Safe Use
HHS also should take steps to help improve information gathering and analysis. This includes promoting the development of new measures for reliably assessing the current state of health IT safety and monitoring for improvements. Currently, no entity is developing such measures. To lead, HHS should fund a new Health IT Safety Council, within an existing voluntary consensus standards organization, that would evaluate criteria for judging the safe use of health IT and the use of health IT to enhance safety.
Promoting Transparency and Accountability
In addition, HHS should establish a mechanism for both vendors and users to report health IT– related deaths, serious injuries, or unsafe conditions. This effort would supplement current private-sector efforts and help quantify patient safety risks. Reporting should be mandatory for vendors, while reporting by users should be voluntary, confidential, and nonpunitive. Strategies also should be developed to encourage reporting; such efforts might include removing any perceptual, contractual, legal, and logistical barriers to reporting.
While improving reporting of patient safety incidents is critical, it is only one part of a larger solution to maximize the safety of health IT– assisted care. Another part is ensuring the ability to learn from and act on this information. To this end, HHS should recommend that Congress establish an independent federal entity—similar to the National Transportation Safety Board—that would perform the needed analytic and investigative functions in a transparent, nonpunitive manner. The entity would make nonbinding recommendations to the Secretary of HHS, providing flexibility and allowing HHS, health care organizations, vendors, and external experts to collectively determine the best course forward.
These and other recommendations would comprise the first stage for action, greatly advancing current understanding of the threats to patient safety. However, because the private sector has not taken substantive action on its own, the committee further recommends that HHS monitor and publicly report on the progress of health IT safety annually, beginning in 2012. If progress is not sufficient, HHS should direct the Food and Drug Administration (FDA) to exercise its authority to regulate health IT. To be effective, the FDA will need to commit sufficient resources and add capacity and expertise to carry this out.
Conclusion
To achieve better health care, a robust infrastructure that supports learning and improving the safety of health IT is essential. Proactive steps must be taken to ensure that health IT is developed and implemented with safety as a primary focus. If appropriately implemented, health IT can help improve health care providers’ performance, better communication between patients and providers, and enhance patient safety, which ultimately may lead to better care for Americans.